Adlai Nortye Taps Lilly and Merck KGaA to Supply Cetuximab for AN4035 Combination Trial
ANL has more than doubled off its 52-week low of $0.879 on elevated volume (1.8× avg).
Summary
Adlai Nortye signed clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany to test its pan-RAS(ON) ADC AN4035 in combination with cetuximab, the anti-EGFR antibody marketed as Erbitux. Both partners will supply cetuximab at no cost — Lilly for U.S. sites, Merck KGaA for Australia and China sites — while Adlai Nortye remains trial sponsor. The combination arm will be added to the ongoing global Phase I study in CEACAM5-enriched, RAS-addicted solid tumors, with monotherapy and combination arms starting on a staggered timeline. This follows the September 8 first-patient dosing in the AN4035 Phase I and the August HREC approval and CTN submission, extending the program's momentum with two large pharma partners now attached. For a clinical-stage company of this size, free drug supply and Big Pharma validation lower development cost and add credibility, though no revenue or efficacy data is involved. Lilly is only a supplier here, not a financial stakeholder, so the direct impact is on Adlai Nortye.
At the time of this announcement, ANL was trading at $11.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $700.6M. The 52-week trading range was $0.88 to $17.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.